Nanoradioenhancer JNJ-1900 Posts 85.7% Response Rate; Ebola Emergency Declared
Nanobiotix and Johnson & Johnson’s nanoradioenhancer JNJ-1900 achieved an 85.7% overall response rate and 57.1% complete response rate in seven patients with stage 3 inoperable non-small cell lung cancer, compared to under 5% complete responses with standard care. Health officials have declared the current Ebola outbreak a public health emergency, potentially heightening demand for Ebola vaccines.
1. Phase 2 CONVERGE Trial Reports High Response Rates
Johnson & Johnson and Nanobiotix’s collaboration on the CONVERGE study evaluating JNJ-1900 (NBTXR3) in stage 3 inoperable non-small cell lung cancer delivered an 85.7% overall response rate and 57.1% complete response rate among seven evaluable patients. These early results substantially exceed the sub-5% complete response rates seen with current standard-of-care radiotherapy, reinforcing JNJ-1900’s potential to strengthen Johnson & Johnson’s oncology pipeline.
2. Ebola Outbreak Sparks Public Health Emergency
Health authorities have declared the latest Ebola outbreak a public health emergency, underscoring the urgent need for effective vaccines and treatments. This designation may accelerate regulatory attention and procurement orders for Ebola vaccines, including those developed by Johnson & Johnson, as containment efforts intensify.